Tower Laboratories, Ltd
Centerbrook, CT, United States
Due-diligence reportFind an accredited testing lab and confirm its scope covers your product and methods.
Tower Laboratories, Ltd is a dietary supplement manufacturer in Centerbrook, CT, United States, certified to NSF/ANSI 455-2 GMP, with 4 manufacturing and packaging facilities on NSF’s public NSF/ANSI 455 listing as of November 19, 2026. Listed dosage forms: powders and tablets.
- Website
- towerlabs.com
- Phone
- 860-767-2127
- Facilities listed
- 4
- Last checked
Dosage forms
As listed in the product categories of this company’s NSF/ANSI 455-2 certified facilities.
Certified facilities
Manufacturing (3)
8 Industrial Park Road, Centerbrook, CT 06409, United States
- Mixing
- Packaging/Labeling Operation
- Packaging/Labeling Operation - Primary Packaging
- Packaging/Labeling Operation - Secondary Packaging
- Quality Unit Operations
- Tablet Compression
- Warehousing
8060 Whitbeck Road, Montague, MI 49437, United States
- Dry Formulation
- Mixing
- Packaging/Labeling Operation
- Packaging/Labeling Operation - Primary Packaging
- Packaging/Labeling Operation - Secondary Packaging
- Quality Unit Operations
- Tablet Compression
- Warehousing
7 Heritage Park Road, Clinton, CT 06413, United States
- Quality Unit Operations
- Warehousing
Packaging (1)
31 Industrial Park Road, Centerbrook, CT 06409, United States
- Packaging/Labeling Operation
- Packaging/Labeling Operation - Primary Packaging
- Packaging/Labeling Operation - Secondary Packaging
- Quality Unit Operations
How Tower Laboratories, Ltd compares
Among the 769 manufacturers we list, as of our last check.
- One of 3 tablet manufacturers we list in Connecticut, and 228 in the United States. All tablet manufacturers in the USA
- One of 3 powder manufacturers we list in Connecticut, and 316 in the United States. All powder manufacturers in the USA
- Has 4 listed manufacturing or packaging facilities; 94% of the manufacturers we list have fewer.
FDA recall records
No food or dietary supplement recall found under the name Tower Laboratories, Ltd in FDA’s enforcement reports, as of .
We match FDA records by company name only. A recall listed under a different name won’t appear here, and a different company with the same name could. FDA’s food enforcement records start in June 2012. How we check
FDA inspections
FDA lists 6 food or dietary supplement inspections at facilities matching Tower Laboratories, Ltd, from 2010 to 2022, as of . 3 found no objectionable conditions and 3 found conditions the firm was left to correct.
No action indicated · No objectionable conditions found
Inspected
Centerbrook, Connecticut
FEI 1219540
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Montague, Michigan
1 citation posted:
- Examination, testing; appropriate (21 CFR 111.320(a))
Full citation text
Examination, testing; appropriate (21 CFR 111.320(a))
You did not verify that the laboratory examination and testing methodologies are appropriate for their intended use.
FEI 1823985
No action indicated · No objectionable conditions found
Inspected
Centerbrook, Connecticut
FEI 1219540
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Centerbrook, Connecticut
9 citations posted:
- Specifications not met - reject, quality control (21 CFR 111.77(a))
- Examination, testing; scientifically valid (21 CFR 111.320(b))
- Approve or reject components, products (21 CFR 211.22(a))
- Absence of Written Procedures (21 CFR 211.100(a))
See all 9 citations
Specifications not met - reject, quality control (21 CFR 111.77(a))
Your quality control personnel did not reject a component and dietary supplement for which a specification was not met.
Examination, testing; scientifically valid (21 CFR 111.320(b))
You did not identify and use an appropriate scientifically valid method for each established specification for which testing or examination is required to determine whether the specification was met.
Approve or reject components, products (21 CFR 211.22(a))
The quality control unit lacks the responsibility and authority to reject all drug products.
Absence of Written Procedures (21 CFR 211.100(a))
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Mixing adequacy (21 CFR 211.110(a)(3))
The in process control procedures were deficient in that they did not include an examination of the adequacy of mixing to assure uniformity and homogeneity.
Procedures for non-sterile drug products (21 CFR 211.113(a))
Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established, written, and followed.
Reprocessing procedures not written or followed (21 CFR 211.115(a))
Procedures prescribing a system for reprocessing batches to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics are not written and followed.
Lab controls established, including changes (21 CFR 211.160(a))
The establishment of specifications including any changes thereto, are not drafted by the appropriate organizational unit and reviewed and approved by the quality control unit.
Test methods (21 CFR 211.165(e))
The reproducibility of test methods have not been established and documented.
FEI 1219540
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Centerbrook, Connecticut
2 citations posted:
- Quality control operations - material review, disposition (21 CFR 111.113)
- Written procedures not established/followed (21 CFR 211.67(b))
Full citation text
Quality control operations - material review, disposition (21 CFR 111.113)
You do not have quality control operations for a material review and disposition decision.
Written procedures not established/followed (21 CFR 211.67(b))
Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
FEI 1219540
Show all 6 inspections
No action indicated · No objectionable conditions found
Inspected
Centerbrook, Connecticut
FEI 1219540
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Montague, Michigan
1 citation posted:
- Examination, testing; appropriate (21 CFR 111.320(a))
Full citation text
Examination, testing; appropriate (21 CFR 111.320(a))
You did not verify that the laboratory examination and testing methodologies are appropriate for their intended use.
FEI 1823985
No action indicated · No objectionable conditions found
Inspected
Centerbrook, Connecticut
FEI 1219540
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Centerbrook, Connecticut
9 citations posted:
- Specifications not met - reject, quality control (21 CFR 111.77(a))
- Examination, testing; scientifically valid (21 CFR 111.320(b))
- Approve or reject components, products (21 CFR 211.22(a))
- Absence of Written Procedures (21 CFR 211.100(a))
See all 9 citations
Specifications not met - reject, quality control (21 CFR 111.77(a))
Your quality control personnel did not reject a component and dietary supplement for which a specification was not met.
Examination, testing; scientifically valid (21 CFR 111.320(b))
You did not identify and use an appropriate scientifically valid method for each established specification for which testing or examination is required to determine whether the specification was met.
Approve or reject components, products (21 CFR 211.22(a))
The quality control unit lacks the responsibility and authority to reject all drug products.
Absence of Written Procedures (21 CFR 211.100(a))
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Mixing adequacy (21 CFR 211.110(a)(3))
The in process control procedures were deficient in that they did not include an examination of the adequacy of mixing to assure uniformity and homogeneity.
Procedures for non-sterile drug products (21 CFR 211.113(a))
Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established, written, and followed.
Reprocessing procedures not written or followed (21 CFR 211.115(a))
Procedures prescribing a system for reprocessing batches to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics are not written and followed.
Lab controls established, including changes (21 CFR 211.160(a))
The establishment of specifications including any changes thereto, are not drafted by the appropriate organizational unit and reviewed and approved by the quality control unit.
Test methods (21 CFR 211.165(e))
The reproducibility of test methods have not been established and documented.
FEI 1219540
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Centerbrook, Connecticut
2 citations posted:
- Quality control operations - material review, disposition (21 CFR 111.113)
- Written procedures not established/followed (21 CFR 211.67(b))
Full citation text
Quality control operations - material review, disposition (21 CFR 111.113)
You do not have quality control operations for a material review and disposition decision.
Written procedures not established/followed (21 CFR 211.67(b))
Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
FEI 1219540
No action indicated · No objectionable conditions found
Inspected
Centerbrook, Connecticut
FEI 1219540
We match FDA inspections to companies by facility ZIP code (or city outside the US) and company name, so an inspection filed under a different name won’t appear here. FDA publishes final classifications only, and holds some back while enforcement is pending. Posted citations may differ from FDA’s final findings. FDA Data Dashboard · How we check
What Tower Laboratories, Ltd says it offers
From Tower Laboratories, Ltd’s own website, checked . Not verified by us.
Products
Vitamins & mineralsShow quoteHide quote“Effervescent Vitamin C Tablets – Orange”
“Effervescent Vitamin C Tablets – Orange”
Source page · seen on
Electrolytes & hydrationShow quoteHide quote“Effervescent Electrolyte Stickpacks – Berry”
“Effervescent Electrolyte Stickpacks – Berry”
Source page · seen on
Services
Custom formulationShow quoteHide quote“Tower Laboratories has expertise in effervescent product development from concept through commercialization.”
“Tower Laboratories has expertise in effervescent product development from concept through commercialization.”
Source page · seen on
Contract manufacturingShow quoteHide quote“Tower Laboratories is the top U.S. effervescent manufacturer, offering FDA-registered contract manufacturing, product development, and private label solutions.”
“Tower Laboratories is the top U.S. effervescent manufacturer, offering FDA-registered contract manufacturing, product development, and private label solutions.”
Source page · seen on
Stick packs & sachetsShow quoteHide quote“We also produce a number of effervescent powders and granulations, which can be packed into moisture resistant pouches, sachets or stick packs.”
“We also produce a number of effervescent powders and granulations, which can be packed into moisture resistant pouches, sachets or stick packs.”
Source page · seen on
We read the company’s public web pages and keep a claim only when its quote appears on the page. A claim is hidden once we haven’t seen it for 120 days. Spotted something wrong? Tell us · How we collect website claims
What we checked, and what we didn’t
Confirmed from NSF’s public listing
Last checked
- NSF/ANSI 455-2 GMP certification
- 4 facility addresses
- Dosage forms in the certified scope
- Operations listed for each facility
Not verified by us
- Minimum order quantity (MOQ): the smallest order they accept
- Lead times and current capacity
- Prices
- Other certifications, like organic, kosher, halal or NSF Certified for Sport
- Whether they’re taking new clients
- Conditions inside the facility. We don’t visit or audit facilities.
- What the company’s own website says it makes and offers, shown above with quotes
Ask about these in your quote request. How we verify
Other tablet manufacturers in the United States
NSF lists 5 tablet facilities, including one in Tempe, AZ
Tempe, AZ, United States21stcenturyvitamins.com
- Capsules
- Gummies
- Softgels
- Tablets
Operations:- Kitting
- Coating
- Tablet compression
- Encapsulation
NSF/ANSI 455-2checked Nov 19, 2026NSF lists 2 tablet facilities, including one in Happauge, NY
Happauge, NY, United Statesazpharmaceutical.com
- Powders
- Tablets
Operations:- Tablet compression
- Dry formulation
NSF/ANSI 455-2checked Nov 19, 2026NSF lists a tablet facility in Garden Grove, CA
Garden Grove, CA, United Statespackaging.com
- Capsules
- Gummies
- Powders
- Softgels
- Tablets
NSF/ANSI 455-2checked Nov 19, 2026Access Business Group, LLC
USDA OrganicNSF lists a tablet facility in Ada, MI
Ada, MI, United Statesamway.com
- Capsules
- Powders
- Softgels
- Tablets
Operations:- Kitting
- Coating
- Tablet compression
- Encapsulation
- +1 more
NSF/ANSI 455-2checked Nov 19, 2026NSF lists a tablet facility in Gilbert, AZ
Gilbert, AZ, United Statesadeptlifesciences.com
- Capsules
- Liquids
- Powders
- Tablets
Operations:- Liquid formulation
- Tablet compression
- Encapsulation
- Dry formulation
NSF/ANSI 455-2checked Nov 19, 2026ADH Health Products, Inc.
USDA OrganicNSF lists a tablet facility in Congers, NY
Congers, NY, United Statesadhhealth.com
- Capsules
- Oils
- Powders
- Tablets
Operations:- Coating
- Tablet compression
- Encapsulation
- Dry formulation
NSF/ANSI 455-2checked Nov 19, 2026